BI
CNTA

BVF Inc’s Centessa Pharmaceuticals CNTA Stock Holding History

BVF Inc’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,774,570
Closed -$69.8M – 64
2023
Q4 		$69.8M Sell
8,774,570
-328,484
-4% -$2.2M 1.75% 15
2023
Q3 		$58.9M Sell
9,103,054
-320,161
-3% -$2.19M 1.59% 18
2023
Q2 		$58.3M Hold
9,423,215
– – 1.63% 18
2023
Q1 		$36.3M Buy
9,423,215
+2,528,870
+37% +$9.25M 1.33% 26
2022
Q4 		$21.4M Hold
6,894,345
– – 0.9% 35
2022
Q3 		$27.7M Hold
6,894,345
– – 1.14% 32
2022
Q2 		$33.6M Buy
6,894,345
+5,138,800
+293% +$32.9M 1.62% 21
2022
Q1 		$15.7M Buy
1,755,545
+1,301,000
+286% +$11.9M 0.63% 41
2021
Q4 		$5.12M Buy
+454,545
New +$6.12M 0.19% 64
2021
Q3 		– Sell
-58,900
Closed -$1.31M – 76
2021
Q2 		$1.31M Buy
+58,900
New +$1.38M 0.05% 69

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc's CNTA Position: Q1 2024 in Review

BVF Inc sold out of Centessa Pharmaceuticals (CNTA) in Q1 2024, closing a stake of 8,774,570 shares — an estimated $69.8M sold.

BVF Inc first reported a position in CNTA in Q2 2021 and held it in 10 quarters. The position peaked at $69.8M in Q4 2023. 69 funds tracked by Wall St. Rank hold CNTA as of Q1 2024.

  • BVF Inc reported no remaining Centessa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • BVF Inc sold 8,774,570 Centessa Pharmaceuticals shares in Q1 2024, an estimated $69.8M.
  • BVF Inc first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • BVF Inc's Centessa Pharmaceuticals position peaked at $69.8M in Q4 2023.
  • 69 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2024.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.